Please login to the form below

Not currently logged in
Email:
Password:

necitumumab

This page shows the latest necitumumab news and features for those working in and with pharma, biotech and healthcare.

Lilly wins on appeal in Alimta vitamin regimen dispute

Lilly wins on appeal in Alimta vitamin regimen dispute

Stemming the decline in Alimta will give Lilly more time to build sales momentum for newer products such as rheumatoid arthritis treatment Olumiant (baricitinib) and NSCLC therapy Portrazza (necitumumab).

Latest news

More from news
Approximately 3 fully matching, plus 17 partially matching documents found.

Latest Intelligence

  • Pharma deals during January 2013 Pharma deals during January 2013

    In a similar vein, Bristol Myers Squibb (BMS) confirmed that it had returned the rights to necitumumab (IMC-11F8) a next generation Erbitux in phase III for non-small cell lung

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Origins Insights

Our goal is to identify and embed transformational patient insights as a fundamental part of the drug development process. As...

Latest intelligence

DATA shutterstock_1818502577-640.jpg
Empowering patients empowers results
Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...
Don’t limit diversity to just representation in clinical trials
What is the power of diversity in the healthcare environment? Can it make clinical trials more inclusive?...
Oh no… not more training
Paul Hutchings, founder of fox&cat, discusses ways to help your team manage pressure in a more human, pressure-centric and engaging way...

Infographics